Skip to main content
. Author manuscript; available in PMC: 2020 Sep 25.
Published in final edited form as: Invest New Drugs. 2019 Jun 6;37(4):755–762. doi: 10.1007/s10637-019-00797-1

Fig. 2.

Fig. 2

(a) Time to progression (censored time marked). Median PFS 1.9 months (95% confidence interval: 1.8–2.0 months); (b) Overall survival (censored time marked). Median OS 8.5 months (95% confidence interval: 5.0–9.8 months)